Bimatoprost: 7 agencies, 2002–2024
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused bimatoprost: all 7 decisive outcomes across 4 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 22.2 years separate the first record, 9 Aug 2002 at SMC (Scotland), from the most recent, 20 Nov 2024 at HAS (France).
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
3 distinct indication wordings are recorded for bimatoprost by the agencies that label one in English (AWMSG, PBAC and SMC).
2 of these 13 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess bimatoprost, on 9 Aug 2002; NYE METODER (Norway) did not open a file until 17 Nov 2024 — an unusually long tail of 22.2 years between the earliest and latest system to look at it.
3 of the 7 agencies here assessed bimatoprost more than once, HAS (France) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for bimatoprost.
The full ledger for bimatoprost reads 6 recommended, 5 other, 1 not assessed and 1 restricted.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 20 Nov 2024 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| NYE METODER (Norway) | 17 Nov 2024 | For reduksjon av intraokulært trykk (IOP) hos voksne med åpenvinklet glaukom eller okulær hypertensjon som er uegnet for… | decision recorded | source |
| AWMSG (Wales) | 9 Nov 2022 | Reduction of intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults (as mono-therapy or a… | outside AWMSG criteria | source |
| PBAC (Australia) | 2022 | Elevated intraocular pressure or open angle glaucoma | The PBAC advised that the July 2020 recommendation be revoked. | source |
| TLV (Sweden) | 12 May 2015 | Lumigan, endos, ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
8 further decisions for bimatoprost, across 4 agencies, are not shown here. They link to 7 further source documents.
Related molecules
- latanoprost — same ATC class S01E — Ophthalmologicals
- travoprost — same ATC class S01E — Ophthalmologicals
- dorzolamide / timolol — same ATC class S01E — Ophthalmologicals
- latanoprost / timolol — same ATC class S01E — Ophthalmologicals
- bimatoprost / timolol — same ATC class S01E — Ophthalmologicals
- latanoprost / netarsudil — same ATC class S01E — Ophthalmologicals
Coverage: 13 decisions for bimatoprost from 7 agencies, 2002 to 2024. Data to 7 Sep 2026. ATC class S01E — Ophthalmologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.